Palatin Technologies Inc PTN
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if PTN is a good fit for your portfolio.
News
-
Palatin Announces Exercise of Warrants for Approximately $6.1 Million Gross Proceeds
-
Palatin Announces the Initiation of a Phase 2 Clinical Study of Bremelanotide Co-Administered with a PDE5i for the Treatment of Erectile Dysfunction (ED)
-
Palatin Initiates Phase 2 Clinical Study of Bremelanotide for the Treatment of Obesity
-
Palatin Reports Third Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update
-
Palatin to Report Third Quarter Fiscal Year 2024 Results; Teleconference and Webcast to be held on May 15, 2024
-
Palatin Announces FDA Clearance of IND Application for the Co-Administration of Bremelanotide with Tirzepatide (GLP-1) for the Treatment of Obesity
-
Palatin to Host Virtual KOL Event "Beyond GLPs: The Multiple Roles for Novel Melanocortin Receptor 4 Agonists in Treating Obesity and Weight Loss Maintenance" on May 8, 2024
Trading Information
- Previous Close Price
- $1.81
- Day Range
- $1.66–1.81
- 52-Week Range
- $1.43–4.65
- Bid/Ask
- $1.70 / $1.80
- Market Cap
- $27.43 Mil
- Volume/Avg
- 67,121 / 130,467
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 4.12
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Palatin Technologies Inc is a part of the healthcare sector. The company is engaged in developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with unmet medical needs and commercial potential. Its programs are based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems. Its main product in clinical development is bremelanotide, which treats hypoactive sexual desire disorder, which is a type of female sexual dysfunction.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 33
- Website
- https://www.palatin.com
Valuation
|
Metric
|
PTN
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 18.50 |
Price/Sales | 4.12 |
Price/Cash Flow | — |
Price/Earnings
PTN
Financial Strength
|
Metric
|
PTN
|
|---|---|
Quick Ratio | 1.17 |
Current Ratio | 1.20 |
Interest Coverage | −2,284.49 |
Quick Ratio
PTN
Profitability
|
Metric
|
PTN
|
|---|---|
Return on Assets (Normalized) | −191.97% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
PTN
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk A/S ADR
NVO
| Rtmmmrkc | Wcqn | $570.2 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Wynwcsnt | Rxrlh | $127.0 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Mnlfljl | Ysxsg | $117.3 Bil | |||
| Moderna Inc
MRNA
| Cnyghwpwz | Dfnyb | $46.1 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Xvhskkp | Pnhmcx | $29.7 Bil | |||
| argenx SE ADR
ARGX
| Bxdmwmmv | Xwyzq | $28.8 Bil | |||
| BioNTech SE ADR
BNTX
| Frmdqqyq | Bfzh | $20.7 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Mnqyvkhy | Vgvyrc | $16.1 Bil | |||
| United Therapeutics Corp
UTHR
| Gdbwzmn | Clph | $14.9 Bil | |||
| Incyte Corp
INCY
| Qxgwklcd | Kknjh | $13.5 Bil |